Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

(OP: SDZNY )

41.47 UNCHANGED
Streaming Delayed Price Updated: 3:58 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SDZNY

< Previous 1 2 Next >
Generic/Biosimilar Player Sandoz Settles US Price Fixing Case For $265M
Sandoz US, settles Generic Pharmaceuticals Pricing Antitrust Litigation for $265 million, addressing claims from direct purchasers without admitting wrongdoing. Post-approval, litigation continues with... 
Via Benzinga
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs
From Sandoz Group
Via GlobeNewswire
Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today?
Coherus BioSciences agreed to sell its ophthalmology franchise for $170M to Sandoz. This aligns with CHRS' focus on oncology and will help reduce debt and overhead costs. 
Via Benzinga
Venue Turmoil: Pharma Companies Oppose States' Bid to Relocate Price-Fixing Cases
Major pharmaceutical firms, including generic manufacturers such as Teva Pharmaceutical Industries Limited (NYSE: TEVA), Sandoz Group (OTC:  
Via Benzinga
Novartis Q3: Earnings Beat, Raised Operating Profit Outlook & More
Novartis AG (NYSE: NVS) reported  
Via Benzinga
Topics Earnings
Exposures Financial
Eli Lilly, McKesson, Novartis Flash Promising Chart Action
Eli Lilly, McKesson, and Novartis are catching investors' attention with promising chart patterns and revenue growth, signaling potential buying opportunities. 
Via MarketBeat
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.